Micklemouse
18-06-2006, 12:37
From http://www.emedicine.com/NEURO/topic417.htm
Status Epilepticus
Last Updated: December 19, 2005
Author: Mark Spitz, MD, Professor, Department of Neurology, University of Colorado Health Sciences Center
Coauthor(s): Frank Lum, MD, Instructor, Department of Neurology, University of Colorado Health Sciences Center; Jose E Cavazos, MD, PhD, Assistant Professor, Departments of Medicine (Neurology) and Pharmacology, University of Texas Health Science Center at San Antonio; Edward Maa, MD, Epilepsy Fellow, Department of Neurology, University of Colorado Health Science Center
Mark Spitz, MD, is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, and American Epilepsy Society
Editor(s): Joseph F Hulihan, MD, Vice President, Medical Affairs, Ortho-McNeil Neurologics, Inc; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Norberto Alvarez, MD, Assistant Professor, Department of Neurology, Harvard Medical School; Consulting Staff, Department of Neurology, Boston Children's Hospital; Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida College of Medicine; and Nicholas Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants
INTRODUCTION
Background: Status epilepticus (SE) is a common, life-threatening neurologic disorder. It is essentially an acute, prolonged epileptic crisis. The first description of SE in the medical literature was in a Babylonian text from the first millennium BC. The author recognized the severity of the condition, "If an epilepsy demon falls many times upon him on a given day, he seven times punishes him and possesses him, his life will be spared. If he falls upon him eight times, his life may not be spared” (Wilson, 1990).
In early studies, SE was defined by its duration, that is, as continuous seizures occurring for longer than 1 hour. Clinical and animal experiences later showed that pathologic changes and prognostic implications occurred when SE persisted for 30 minutes. Therefore, the time for the definition was shortened. The working group on SE of the Epilepsy Foundation (formerly the Epilepsy Foundation of America) formulated the current definition: "More than 30 minutes of continuous seizure activity or two or more sequential seizures without full recovery of consciousness between seizures." (Dodson, 1993). More recently, authors suggest that SE be defined as any seizure lasting longer than 5 minutes based on natural history data that show typical generalized convulsive seizures that resolve spontaneously after 3-5 minutes (Lowenstein).
Treiman classification
The predominant type of seizure further refines the definition of SE, and several classification schemes have been proposed. Rona and Luders (2005) have suggested a detailed semiologic classification along 3 axes: (1) the type of brain function predominantly compromised, (2) the body part involved, and (3) The evolution over time. However, Celesia (1976) and Treiman (1994) proposed simpler schemes, which are still more useful than other systems for emergency treatment decisions.
The Treiman classification is used in this article, as follows:
* Generalized convulsive SE
* Subtle SE
* Nonconvulsive SE
o Absence SE
o Complex partial SE
* Simple partial SE
The most frequent and potentially dangerous type of SE is generalized convulsive SE, which is the subject of most of this article. Nonconvulsive SE and partial SE are discussed briefly.
Subtle SE
Although subtle SE is, by definition, nonconvulsive, it should be distinguished from other nonconvulsive types of SE. The prognosis of patients with subtle SE, contrary to those with nonconvulsive SE, is dismal. It is considered the most severe clinical stage of generalized convulsive SE, and is characterized by a dissociation between the electrical brain activity and the predicted motoric response of generalized convulsive SE.
Nonconvulsive SE
Nonconvulsive SE is divided into 2 categories, absence SE and complex partial SE. Differentiating these subtypes is important, since they indicate major differences in treatment, etiology, and prognosis.
Absence SE
On clinical presentation, a clear change in the level of consciousness is observed. Most patients are not comatose but lethargic and confused, with decreased spontaneity and slow speech.
The ictal electroencephalograph (EEG) during typical absence SE demonstrates generalized spike and wave discharges. The frequency may be slower than 3 Hz, and the waveforms (though bilaterally synchronous) are often irregular, poorly formed, and discontinuous, especially in the late stages. In adults and in some children, the apparently bisynchronous EEF discharges may represent complex partial SE as opposed to true absence SE.
About 3% of patients with previous absence seizures have absence status (Lennox, 1960). Approximately 10% of adults with childhood-onset absence seizures experience absence SE (Cascino, 1993). About 75% of all cases of absence SE occur before the age of 20 years. When it occurs in adults, the patients are often elderly. The mean age of onset of absence SE in adults is 51 years (Porter, 1983).
Typical absence SE that occurs in children or adolescents who have primary or idiopathic generalized epilepsy (which includes absence seizures) readily responds to treatment. In contrast, absence SE in the symptomatic, primary generalized epilepsies (eg, Lennox-Gastaut syndrome) is often more difficult to control.
The following issues should be considered in the differential diagnoses of absence SE: (1) Complex partial SE usually manifests with recurring cycles of 2 separate phases: ictal and interictal. In contrast, absence SE usually occurs as 1 continuous episode of variable intensity. (2) Stereotyped automatisms can be seen in both complex partial and absence SE, though they tend to be richer in complex partial SE than in absence SE. Anxiety, aggression, fear, and irritability may be most common in complex partial SE, but they can be seen in both types. (3) EEG is the best way to differentiate absence SE from complex partial SE. (4) Other possibilities include a postictal state and encephalopathies from toxic-metabolic causes, drugs, trauma, or infection. Psychiatric causes should be considered.
No deaths or long-term morbidity due to typical absence SE have been reported. Whether absence SE in children with developmental dementia and myoclonic/astatic epilepsy is injurious to the brain is controversial. Differentiating absence SE from other causes is important because many mimics of absence SE can lead to irreversible neuronal damage if they are not aggressively treated.
Benzodiazepines and valproate are the treatments of choice. Valproic acid is available in intravenous (IV) form. The theoretical advantage is that it can be continued long term after the acute episode. Valproate is loaded at a dose of 25 mg/kg IV in a 50-mL solution and infused over 10 minutes. The next dose is given 3 hours later, after which every-6-hour dosing can be started. The drug should never be given intramuscularly (IM). Ethosuximide also can be useful, but is not available in parenteral form.
Complex partial SE
Complex partial SE is rare. Although many cases of prolonged complex partial SE have been described without long-term neurologic sequelae, negative outcomes can occur. No method to differentiate the cases associated with a poor outcome is known.
In patients with isolated complex partial seizures, the origin is usually in the temporal lobe. In contrast, patients with complex partial SE usually have an extratemporal focus. Shorvon (1995) believes that at least 15% of patients with complex partial epilepsy have a history of nonconvulsive SE.
Treatment is the same as that for convulsive SE.
Simple partial SE
By definition, simple partial SE consists of seizures localized to a discrete area of cerebral cortex, and it does not alter consciousness. Because this form is rare, no good studies have been done to determine its incidence.
Diagnosis is primarily based on clinical findings. Because of the relatively small area of cerebral cortical involvement, results of conventional scalp EEG are frequently uncharacteristic of the clinical ictal activity, or they may be normal.
Simple partial SE, in contrast to convulsive SE, is not associated high rates of morbidity or mortality. Outcomes seem to be related to the underlying etiology, the duration of the SE, the age of the patient, and the medical complications, as in convulsive SE. Treatment involves the same drugs and general pharmacologic principles as those used for convulsive SE. However, the relatively low morbidity and mortality rates suggest that aggressive treatment might not be needed. For example, if first-line drugs are ineffective, the clinician may elect not to use a general anesthetic agent to stop simple partial SE.
Pathophysiology: Numerous systemic and primary brain changes occur during convulsive SE. Most evidence suggests that permanent brain damage is caused more by ongoing seizure activity than by systemic factors. Neuropathologic animal studies by Meldrum and Horton (1973) demonstrated that prolonged seizure activity results in pathologic changes after 30 minutes; after 60 minutes, neurons begin to die. These observations parallel findings in human clinical studies, which have shown that the duration of SE is directly correlated with morbidity and mortality rates. The longer the SE persists, the more likely that neurons are damaged by excitatory neurotransmitters. Sustained seizure activity also progressively reduces gamma- aminobutyric acid (GABA) inhibition.
Several important systemic changes are associated with generalized convulsive SE.
In the early stages of SE, prominent elevation in systemic arterial pressure is seen. In a study of 21 patients, White et al (1961) found a mean elevation of systolic pressure of 85 mm Hg and an elevation of diastolic pressure of 42 mm Hg. As SE continues, blood pressures may decrease to levels below their former baseline.
Marked acidosis usually occurs. In a study of 70 spontaneously ventilating patients with SE, 23 had a pH of less than 7.0 (Aminoff, 1980). The acidosis has both a respiratory and a metabolic component, but it usually should not be treated. The induced acidosis is not correlated with the degree of neuronal injury, and acidosis is known to be an anticonvulsant.
Convulsive SE affects not only the mechanical aspects of breathing but also causes pulmonary edema. Many of the medications used to treat SE (specifically benzodiazepines and barbiturates) inhibit respiratory drive both individually and synergistically when given in combination. A patient who has already received a full loading dose of benzodiazepines and who is being given barbiturates for convulsive status epilepticus should be electively intubated before this combination is administered.
* Hyperthermia, which frequently occurs in SE, is caused by motor activity as well as central sympathetic drive. In 90 patients with SE, 75 had hyperthermia with temperatures reaching 42oC (Aminoff, 1980). Hyperthermia has been correlated with poor neurologic outcomes and should be treated aggressively.
* A mild leukocytosis (primarily due to demargination) is common in both blood and CSF. In a study of 80 patients, 50 without evidence of infection had WBC elevations from 12.7-28.8 X 109/L (12,700-28,800 cells/mm3). Bands should not be seen. CSF pleocytosis is common but the cell-count elevations are usually modest. In 1 study, only 4 of 65 patients had >30 cells in the CSF (Aminoff, 1980).
Frequency:
* In the US: Extrapolating from a population-based study in Richmond, VA, DeLorenzo et al (1996) estimated that 50,000-200,000 cases occur annually in the United States.
Mortality/Morbidity: Mortality rates related to SE have decreased over the last 60 years, probably in relation to faster diagnosis and more aggressive treatment than before.
The probability of death is closely correlated with age. In prospective population-based studies, DeLorenzo et al (2001) found that the overall mortality rate was 22% for the entire population, 13% for young adults, 38% for the elderly, and >50% for those older than 80 years.
* For generalized convulsive SE, the mortality rate in is high. In the 1998 Veterans Administration (VA) study, the SE Cooperative Study Group reported mortality rates of 27% for overt generalized convulsive SE and 65% for subtle generalized convulsive SE. DeLorenzo et al (1995) reported a mortality rate of 21% in patients with generalized SE, defining mortality as death occurring within 30 days. Aicardi and Chevrie (1970) examined 239 children with generalized convulsive SE that lasted longer than an hour. Twenty-six died, and 88 had permanent neurologic damage (47 of whom had been neurologically intact before the episode).
* According to Hauser (1990), no more than 2% of patients die directly from SE, and severe systemic disease and an acute CNS insult in association with the SE are predictive of a poor outcome.
* In a prospective study of 24 patients who died, 10 had a gradual decrease in mean arterial pressure and/or heart rate. The remaining 14 had no cardiac changes until the time of death. About 90% of patients with cardiac decompensation had a history of many risk factors for atherosclerotic cardiovascular disease, whereas only 30% of those without acute cardiac decompensation had clinically significant risk factors (Boggs, 1998).
Age: Most cases of SE, up to 70%, occur in children. However, the incidence of SE is highest in the population older than 60 years, at 83 cases per 100,000 population (Waterhouse, 2001).
See also Mortality/Morbidity above and Causes below.
CLINICAL
History:
* Generalized convulsive SE is usually easy to diagnose, but an understanding of its evolution from overt convulsions through subtle SE is important. Patients may present with an undramatic clinical picture if they have subtle SE at the time of presentation.
* Treiman and co-workers (1990, 1992, 1995) described the clinical and EEG changes accompanying generalized convulsive SE.
o The event usually begins with a series of generalized tonic, clonic, or tonic-clonic seizures that often are dramatic.
+ Each seizure is discrete; the motor activity stops abruptly, coincident with the end of the electrographic seizure.
+ Each convulsion is followed by gradual recovery, and then the next seizure occurs.
o If the condition is not treated or is treated inadequately, SE persists, and the motor manifestations become less dramatic than before.
+ Eventually, only subtle movements (eg, nystagmoid jerks of the eyes or twitching of the shoulder) may be seen, that is, subtle status.
+ If SE continues, all motor activity may stop, though EEG seizures persist (ie, electrical generalized convulsive SE).
* The paradoxical evolution of apparent clinical improvement is important to understand. The clinician unfamiliar with this phenomenon may stop treatment because of the apparent improvement.
o Treatment should be continued until the EEG seizure activity has resolved completely.
o In some patients, the underlying encephalopathic insult is so severe that only a few (or no) generalized convulsions occur before subtle convulsive activity develops.
o Finally, as the patient evolves from generalized tonic-clonic status into subtle and then electrical generalized tonic-clonic SE, the manifestations become less intermittent and more continuous than before.
Physical: A number of features on physical examination may provide information about the underlying cause of SE. Evidence of track marks might suggest SE secondary to the use of illicit, or street, drugs. Features on neurologic examination can also be helpful. Papilledema, a sign of increased intracranial pressure, suggests a possible mass lesion or brain infection. Lateralized neurologic features, such as increased tone, asymmetric reflexes, or lateralized features of the movement during SE itself, are suggestive of the seizures beginning in a localized region of the brain, and they may suggest a structural brain abnormality.
Causes:
* Many patients who present in convulsive SE do not have a history of seizures.
o In people with known epilepsy, the most common cause is a change in medication; the change may be directed by physician or due to intentional or unintentional and abrupt cessation (eg, being placed on nothing-by-mouth [NPO] status before surgery). Pharmacologic nonadherence is the most common cause of SE in patients with known epilepsy.
o Other causes include head trauma, stroke, cardiac arrest, CNS infection, and neoplasm.
* Age significantly affects etiology of SE.
o In patients younger than 16 years, the most common cause was fever and/or infection (36%); in contrast, this accounted for only 5% in adults (DeLorenzo, 1995).
o The same study revealed that the most common precipitant in adults was cerebrovascular disease (25%), whereas this factor caused only 3% of pediatric cases.
o In a more refined study that focused on children, Shinnar et al (1997) found that more than 80% of children younger than 2 years had SE of febrile or acute symptomatic origin, whereas cryptogenic and remote symptomatic causes were more common in older children than in younger children.
* In more recent series of SE, HIV infection and use of illicit drugs were reported with increased frequency.
* Other diagnostic considerations include nonepileptic seizures (NES) and abnormal behaviors.
o Formerly called psychogenic seizures, NES, have been known to cause continuous, convulsive activity of concern in SE. Although rare, NES must be considered. SE is associated with several behavioral characteristics that help distinguish it from a nonepileptic event. Epileptic seizures usually have the following characteristics:
+ The seizures are stereotyped. If seizures with bizarre behaviors are stereotyped, they are often true epileptic seizures.
+ The convulsive activity is sustained without pauses. Motor activity during a NES often is punctuated by brief periods of rest. Epileptic convulsions are usually sustained without pause until the end of each individual seizure.
+ During an epileptic seizure, behaviors stereotypically and predictably evolve.
+ When seizure activity spreads, it usually follows the organization of the homunculus.
o Behaviors, such as pelvic thrusting, head turning from side to side, and bizarre vocalizations are usually not seen in epileptic seizures.
+ The exception to this rule is seizure of frontal-lobe onset.
+ Although clinical features are usually helpful, the ultimate test to differentiate between epileptic seizures and NES is EEG.
DIFFERENTIALS
Complex Partial Seizures
Epilepsia Partialis Continua
Frontal Lobe Epilepsy
Seizures and Epilepsy: Overview and Classification
Shuddering Attacks
Simple Partial Seizures
Temporal Lobe Epilepsy
Tonic-Clonic Seizures
Uremic Encephalopathy
Other Problems to be Considered:
Complex partial SE
Subtle seizures
Tonic seizures
Epilepsia Partialis Continua
Frontal Lobe Epilepsy
Seizures and Epilepsy: Overview and Classification
Shuddering Attacks
Simple Partial Seizures
Temporal Lobe Epilepsy
Tonic-Clonic Seizures
Uremic Encephalopathy
WORKUP
Lab Studies:
* Laboratory studies that should be obtained on an emergency basis include a determination of electrolyte, calcium, magnesium, and glucose levels (see Image 1).
* A CBC and renal function tests, arterial blood gas analysis, toxicologic screening, and anticonvulsant levels are often helpful.
* Blood culture, urinalysis, and lumbar puncture (after neuroimaging to rule out potential cerebral herniation) are indicated if an infectious etiology is suspected.
Imaging Studies:
* CT scanning of the brain is often helpful in evaluating for a structural lesion (eg, brain tumor, infarction, abscess, hemorrhage) that may underlie SE. However, a neuroimaging study should never be allowed to impede rapid and aggressive treatment of the disorder.
* Brain MRI is rarely indicated in the acute phase. Although MRI provides more information than CT, it is more time consuming, and the additional information rarely affects immediate treatment and evaluation.
* The utility of MRI continues to evolve, and MRI changes observed during prolonged SE have been reported; such findings reflect the pathophysiology of the condition (Sirven, 2003).
Other Tests:
* Some authors believe that EEG should be a routine part of treatment (Brenner, 2004).
* DeLorenzo et al (1998) prospectively examined 64 patients who clinically appeared to have controlled SE. These patients were comatose and had no overt clinical signs of convulsive activity. However, EEG demonstrated persistent seizures in 48%, and 14% of these patients had nonconvulsive SE (predominantly of the complex partial type).
TREATMENT
Medical Care: Both generalized tonic-clonic style status epilepticus and subtle status epilepticus must be treated aggressively. Maintenance of vital signs, including respiratory function, are of major importance. Any indication of respiratory insufficiency should be addressed by intubation. Finally, systemic acidosis is not a major concern because it is usually transient, and medical treatment to normalize acidosis can lead to a rebound metabolic alkalosis when the status epilepticus stops. In addition, evidence suggests that acidosis has antiseizure effects.
SE must be treated rapidly. Therefore, the treating physician should not wait for a blood level to return from a laboratory test before given the patient a loading dose of phenytoin. The same protocol should be followed regardless of whether the patient is already taking phenytoin. Assume that the patient is noncompliant because this is the most common cause of SE in patients with known epilepsy. Even if the patient has been compliant and even the phenytoin levels were already in the therapeutic range (10-20 mg/mL), data suggest that 20-30 mg/mL is more effective than of 10-20 mg/mL in stopping seizures.
High doses can cause ataxia and sedation. Because the patient is likely to be hospitalized after the SE is controlled, these adverse effects are less important than they would be in a patient being treated on an outpatient basis. SE is a life-threatening situation, and the patient will be admitted to the hospital after treatment. Therefore, if treatment errs, it should err on the side of excessive medication. Temporary adverse effects are preferred to irreversible brain damage or death.
* No reports of prospective, double-blind studies on the treatment of SE have been published recently. Therefore, the best initial drug treatment remains uncertain.
* Treiman et al (1998) compared treatments for generalized convulsive SE, investigating the use of diazepam followed by phenytoin, lorazepam, phenobarbital, or phenytoin.
o As an initial IV treatment for overt generalized convulsive SE, lorazepam was more effective than phenytoin alone.
o Although lorazepam was no more effective than phenobarbital or diazepam plus phenytoin, it was easier to use.
o Not studied was fosphenytoin, a newer drug than the others that is theoretically a significant improvement over phenytoin.
* The duration, underlying etiology, EEG pattern, and clinical presentation at the start of treatment largely determine the response to treatment.
o The more advanced the stage of SE, the less favorable the response to treatment.
o In the recently completed VA Cooperative study, 56% of patients who were first seen with overt, generalized convulsive SE responded to initial treatment. Only 15% of the individuals with subtle, generalized convulsive SE responded to initial treatment (Treiman, 1998).
Surgical Care: Surgical treatment, which consists of ablating a structural abnormality, hemispherectomy, subpial resection or vagal-nerve stimulator placement, is a last-resort maneuver that is rarely performed (D'Giano, 2001; Ma, 2001; Winston; 2001; Duane, 2004).
Consultations:
* Clinicians other than neurologists usually begin treatment for SE because most patients who present with SE have never had a seizure.
* When first- and second-line pharmacologic therapies fail, an anesthesiologist may be needed to perform intubation and administer general anesthesia.
* A neurologist should be obtained, especially if the patient's condition is not responding to initial therapy and if EEG is needed.
MEDICATION
Most patients who are treated aggressively with a benzodiazepine, fosphenytoin, and/or phenobarbital experience complete cessation of their seizures. If SE does not stop, general anesthesia is indicated. No reports of prospective studies on the treatment of refractory SE have been published; however, investigators from retrospective reviews have described the use of pentobarbital, thiopental, midazolam infusion, propofol, levetiracetam, topiramate, valproate, and inhaled anesthetic agents.
Drug Category: Anticonvulsant agents -- A useful algorithm for the treatment of SE is as follows (see Image 1):
* Start an IV line, administer a 50-mL bolus of 50% dextrose IV, then start the anticonvulsant.
* Administer diazepam or lorazepam 0.15 mg/kg IV over 5 minutes, followed by fosphenytoin 15-20 mg phenytoin equivalents (PE)/kg at a rate not to exceed 150 mg/min.
* Intubate if necessary, and control hyperthermia.
* If seizures continue after 20 minutes, give additional fosphenytoin 10 mg PE/kg.
* If seizures continue after 20 minutes, give additional fosphenytoin 10 mg PE/kg.
* If seizures continue, administer general anesthesia.
Drug Name
Diazepam (Valium) -- Extremely lipid-soluble agent that quickly enters brain in first pass and often stops seizures in 1-2 min. Rapidly distributes to other stores of body fat. Serum concentration decreases to 20% of maximum concentration (Cmax) 20 min after IV infusion.
Adult Dose 0.1 mg/kg IV q5min, repeat prn; not to exceed 30 mg in 8 h
Pediatric Dose 0.1 mg/kg IV q5min, repeat prn; not to exceed 30 mg in 8 h
Contraindications Documented hypersensitivity
Interactions None reported as contraindicated for this indication
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions None reported for this indication
Drug Name
Lorazepam (Ativan) -- Less fat-soluble benzodiazepine than diazepam and therefore takes 5-10 min to stop seizures, and has smaller volume of distribution. Serum concentrations 50% of Cmax at 20 min.
Adult Dose 0.1 mg/kg IV slowly over 2-5 min; repeat in 10-15 min prn; not to exceed 8 mg dose
Pediatric Dose 0.1 mg/kg IV slowly over 2-5 min; repeat prn in 10-15 min at 0.05 mg/kg; not to exceed 4 mg/dose
Contraindications Documented hypersensitivity
Interactions None reported as contraindicated for this indication
Pregnancy D - Unsafe in pregnancy
Precautions None reported for this indication
Drug Name
Phenytoin (Dilantin) -- Mainstay in treatment of SE. Must be administered slowly and therefore takes longer to enter brain than benzodiazepines. Has advantage of being long-term anticonvulsant and can be administered PO after acute illness. Not water soluble, and must be solubilized in propylene glycol carrier with pH 12 to prepare IV form; therefore, cannot be given >50 mg/min without risk of significant hypotension and cardiac arrhythmias. Also major risk of potential irritation at IV site and vascular compromise of infused limb. Therefore, use in SE should be avoided if possible.
Adult Dose 15-20 mg/kg IV, not to exceed 50 mg/min; intubate if necessary and control hyperthermia; if seizures continue after 20 min, give additional 10 mg/kg; target levels after correction of hypoalbuminemia should be 20-30 mcg/mL in SE
Pediatric Dose Administer as in adults
Contraindications Documented hypersensitivity
Interactions None reported as contraindicated for this indication
Pregnancy C - Safety for use during pregnancy has not been established.
Precautions Risk of hypotension and cardiac arrhythmias (perform cardiac monitoring during infusion); infusion rate should be <50 mg/min
Drug Name
Fosphenytoin (Cerebyx) -- Phosphorylated phenytoin prodrug. Highly water-soluble and therefore easier to administer than phenytoin. Enzymatically converted to phenytoin after mean 8 min and therefore can be administered more rapidly than standard phenytoin.
Adult Dose 20 mg/kg PE IV; if seizures do not end give additional 10 mg PE/kg; target levels after correction of hypoalbuminemia should be 20-30 PE/ml for SE
Pediatric Dose 20 mg/kg PE IV; if seizures do not end, give additional 10 mg PE/kg
Contraindications Documented hypersensitivity
Interactions None reported as contraindicated for this indication
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Risk of hypotension and cardiac arrhythmias (perform cardiac monitoring during infusion); infusion rate should be <150 mg/min
Drug Name
Phenobarbital (Luminal, Barbita) -- Best studied barbiturate in treatment of SE. Can be administered 20 mg/min IV. If patient has received benzodiazepine, potential for respiratory suppression significantly increased.
Adult Dose 20 mg/kg IV q20min until seizures controlled or total 1-2 g administered
Pediatric Dose 20 mg/kg IV over 10-15 min in single or divided dose until seizure controlled or 40 mg/kg administered
Contraindications Documented hypersensitivity
Interactions Combination with benzodiazepines causes significant respiratory depression; strongly consider elective intubation before combination given
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions None reported for this indication
FOLLOW-UP
Prognosis:
* The outcome of status epilepticus is directly correlated with its duration.
Patient Education:
* For excellent patient education resources, visit eMedicine's Brain and Nervous System Center. Also, see eMedicine's patient education article Seizures Emergencies and Epilepsy.
Bibliography
* Aicardi J, Chevrie JJ: Convulsive status epilepticus in infants and children. A study of 239 cases. Epilepsia 1970 Jun; 11(2): 187-97[Medline].
* Aicardi J, Chevrie JJ: Consequences of status epilepticus in infants and children. Adv Neurol 1983; 34: 115-25[Medline].
* Aminoff MJ, Simon RP: Status epilepticus. Causes, clinical features and consequences in 98 patients. Am J Med 1980 Nov; 69(5): 657-66[Medline].
* Barry E, Hauser WA: Status epilepticus: the interaction of epilepsy and acute brain disease. Neurology 1993 Aug; 43(8): 1473-8[Medline].
* Barry E, Hauser WA: Pleocytosis after status epilepticus. Arch Neurol 1994 Feb; 51(2): 190-3[Medline].
* Berkovic SF, Andermann F, Guberman A, et al: Valproate prevents the recurrence of absence status. Neurology 1989 Oct; 39(10): 1294-7[Medline].
* Berkovic SF, Bladin PF: Absence status in adults. Clin Exp Neurol 1983; 19: 198-207[Medline].
* Boggs JG, Marmarou A, Agnew JP, et al: Hemodynamic monitoring prior to and at the time of death in status epilepticus. Epilepsy Res 1998 Aug; 31(3): 199-209[Medline].
* Brenner RP: EEG in convulsive and nonconvulsive status epilepticus. J Clin Neurophysiol 2004 Sep-Oct; 21(5): 319-31[Medline].
* Cascino GD: Nonconvulsive status epilepticus in adults and children. Epilepsia 1993; 34 Suppl 1: S21-8[Medline].
* Cascino GD, Hesdorffer D, Logroscino G: Morbidity of nonfebrile status epilepticus in Rochester, Minnesota, 1965-1984. Epilepsia 1998 Aug; 39(8): 829-32[Medline].
* Celesia GG: Modern concepts of status epilepticus. JAMA 1976 Apr 12; 235(15): 1571-4[Medline].
* Christensen RC, Szlabowicz JW: Factitious status epilepticus as a particular form of Munchausen's syndrome. Neurology 1991 Dec; 41(12): 2009-10[Medline].
* D'Giano CH, Del C Garcia M, Pomata H, Rabinowicz AL: Treatment of refractory partial status epilepticus with multiple subpial transection: case report. Seizure 2001 Jul; 10(5): 382-5[Medline].
* DeLorenzo RJ, Hauser WA, Towne AR, et al: A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996 Apr; 46(4): 1029-35[Medline].
* DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG: Epidemiology of status epilepticus. J Clin Neurophysiol 1995 Jul; 12(4): 316-25[Medline].
* DeLorenzo RJ, Towne AR, Pellock JM, Ko D: Status epilepticus in children, adults, and the elderly. Epilepsia 1992; 33 Suppl 4: S15-25[Medline].
* DeLorenzo RJ, Waterhouse EJ, Towne AR, et al: Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998 Aug; 39(8): 833-40[Medline].
* Doose H, Volzke E: Petit mal status in early childhood and dementia. Neuropadiatrie 1979 Feb; 10(1): 10-4[Medline].
* Duane DC, Ng YT, Rekate HL, et al: Treatment of refractory status epilepticus with hemispherectomy. Epilepsia 2004 Aug; 45(8): 1001-4[Medline].
* Epilepsy Foundation of America: Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993 Aug 18; 270(7): 854-9[Medline].
* Fischer JH, Raineri DL: Pentobarbital anesthesia for status epilepticus. Clin Pharm 1987 Aug; 6(8): 601-2[Medline].
* Granner MA, Lee SI: Nonconvulsive status epilepticus: EEG analysis in a large series. Epilepsia 1994 Jan-Feb; 35(1): 42-7[Medline].
* Guberman A, Cantu-Reyna G, Stuss D, Broughton R: Nonconvulsive generalized status epilepticus: clinical features, neuropsychological testing, and long-term follow-up. Neurology 1986 Oct; 36(10): 1284-91[Medline].
* Hauser WA: Status epilepticus: epidemiologic considerations. Neurology 1990 May; 40(5 Suppl 2): 9-13[Medline].
* Janz D: Conditions and causes of status epilepticus. Epilepsia 1961 Jun; 2: 170-7[Medline].
* Leppik IE, Boucher BA, Wilder BJ, et al: Pharmacokinetics and safety of a phenytoin prodrug given i.v. or i.m. in patients. Neurology 1990 Mar; 40(3 Pt 1): 456-60[Medline].
* Lothman E: The biochemical basis and pathophysiology of status epilepticus. Neurology 1990 May; 40(5 Suppl 2): 13-23[Medline].
* Ma X, Liporace J, Sperling MR: Neurosurgical treatment of medically intractable status epilepticus. Epilepsy Res 2001; 46(1): 33-8.
* Meldrum BS, Horton RW: Physiology of status epilepticus in primates. Arch Neurol 1973 Jan; 28(1): 1-9[Medline].
* Meldrum BS: Metabolic factors during prolonged seizures and their relation to nerve cell death. Adv Neurol 1983; 34: 261-75[Medline].
* Meldrum BS, Vigouroux RA, Brierley JB: Systemic factors and epileptic brain damage. Prolonged seizures in paralyzed, artificially ventilated baboons. Arch Neurol 1973 Aug; 29(2): 82-7[Medline].
* Meldrum BS: Excitotoxicity and selective neuronal loss in epilepsy. Brain Pathol 1993 Oct; 3(4): 405-12[Medline].
* Pakalnis A, Drake ME Jr, Phillips B: Neuropsychiatric aspects of psychogenic status epilepticus. Neurology 1991 Jul; 41(7): 1104-6[Medline].
* Parent JM, Lowenstein DH: Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology 1994 Oct; 44(10): 1837-40[Medline].
* Porter RJ, Penry JK: Petit mal status. In: Delgado-Escueta AV, Wasterlain CG, Treiman DM, Porter RJ, eds. Status Epilepticus. New York: Raven Press 1983; 61-7.
* Rona S, Luders HO: A semiological classification of status epilepticus. Epileptic Disord. 2005 March; 7(1): 5-12.
* Shinnar S, Pellock JM, Moshe SL, et al: In whom does status epilepticus occur: age-related differences in children. Epilepsia 1997 Aug; 38(8): 907-14[Medline].
* Shorvon S: Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. New York, NY: Cambridge University Press; 1994.
* Siesjo BK, Ingvar M, Folbergrova J, Chapman AG: Local cerebral circulation and metabolism in bicuculline-induced status epilepticus: relevance for development of cell damage. Adv Neurol 1983; 34: 217-30[Medline].
* Simon RP: Physiologic consequences of status epilepticus. Epilepsia 1985; 26 Suppl 1: S58-66[Medline].
* Sirven JI, Zimmerman RS, Carter JL, et al: MRI changes in status epilepticus. Neurology 2003 Jun 10; 60(11): 1866[Medline].
* Soffer D, Melamed E, Assaf Y, Cotev S: Hemispheric brain damage in unilateral status epilepticus. Ann Neurol 1986 Dec; 20(6): 737-40[Medline].
* Stecker MM, Kramer TH, Raps EC, et al: Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998 Jan; 39(1): 18-26[Medline].
* Thomas P, Beaumanoir A, Genton P, et al: 'De novo' absence status of late onset: report of 11 cases. Neurology 1992 Jan; 42(1): 104-10[Medline].
* Tomson T, Svanborg E, Wedlund JE: Nonconvulsive status epilepticus: high incidence of complex partial status. Epilepsia 1986 May-Jun; 27(3): 276-85[Medline].
* Tomson T, Lindbom U, Nilsson BY: Nonconvulsive status epilepticus in adults: thirty-two consecutive patients from a general hospital population. Epilepsia 1992 Sep-Oct; 33(5): 829-35[Medline].
* Towne AR, Pellock JM, Ko D, DeLorenzo RJ: Determinants of mortality in status epilepticus. Epilepsia 1994 Jan-Feb; 35(1): 27-34[Medline].
* Treiman DM, Walton NY, Kendrick C: A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Res 1990 Jan-Feb; 5(1): 49-60[Medline].
* Treiman DM, Meyers PD, Walton NY: DVA Status Epilepticus Cooperative Study Group. Duration of generalized convulsive status epilepticus: relationship to clinical symptomatology and response to treatment. Epilepsia 1992; 33(Suppl 3): 66.
* Treiman DM, Meyers PD, Walton NY: DVA Status Epilepticus Cooperative Study Group. Factors that predict prognosis in generalized convulsive status epilepticus. Epilepsia 1993; 34(Suppl 6): 30.
* Treiman DM: Generalized convulsive, nonconvulsive, and focal status epilepticus. In: Feldman E, ed. Current Diagnosis in Neurology. St. Louis: Mosby-Year Book; 1994: 11-8.
* Treiman DM: Electroclinical features of status epilepticus. J Clin Neurophysiol 1995 Jul; 12(4): 343-62[Medline].
* Treiman DM, Meyers PD, Walton NY: A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998 Sep 17; 339(12): 792-8[Medline].
* Waterhouse, EJ, DeLorenzo RJ: Status epilepticus in older patients: epidemiology and treatment options. Drugs Aging 2001; 18 (2): 133-142.
* White PT, Grant P, Mosier J, Craig A: Changes in cerebral dynamics associated with seizures. Neurology 1961 Apr; 11(4)Pt 1: 354-61[Medline].
* Wieshmann UC, Woermann FG, Lemieux L, et al: Development of hippocampal atrophy: a serial magnetic resonance imaging study in a patient who developed epilepsy after generalized status epilepticus. Epilepsia 1997 Nov; 38(11): 1238-41[Medline].
* Wilson JV, Reynolds EH: Texts and documents. Translation and analysis of a cuneiform text forming part of a Babylonian treatise on epilepsy. Med Hist 1990 Apr; 34(2): 185-98[Medline].
* Winston KR, Levisohn P, Miller BR, Freeman J: Vagal nerve stimulation for status epilepticus. Pediatr Neurosurg 2001 Apr; 34(4): 190-2[Medline]